{"denoms":[{"counts":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"8"}],"units":"Participants"}],"groups":[{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib:\n\nPhase I: Level -1 = 20 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"BG000","title":"Level -1 = 20 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib:\n\nPhase I: Level 0 = 40 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"BG001","title":"Level 0 = 40 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib:\n\nPhase I: Level +1 = 60 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"BG002","title":"Level +1 = 60 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG003","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG003","value":"3"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG003","value":"5"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG003","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG003","value":"5"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG003","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG003","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG003","value":"5"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG003","value":"8"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"We only included the 8 subjects that passed eligibility and were dosed."}